Log in

Start Your Membership Now

On September 27, 2018, UPMC Health Plan announced it started a value-based contract with Boehringer Ingelheim for Jardiance, an oral medication to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The contract goes live on January 1, 2019. The contract links reimbursement of the drug to costs associated with clinical outcomes among UPMC members who use Jardiance. Reimbursement for the medication will be linked to total costs of care for all people with diabetes treated. Previous contracts for Jardiance measured costs only in those with existing heart disease. UPMC Health Plan . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: